The National Institute for Health and Care Excellence (NICE)
Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism1
This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots) and deep vein thrombosis (DVT) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.
For further information visit: https://www.nice.org.uk/guidance/ng89
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing2
This guideline covers the diagnosis and management of venous thromboembolic diseases in adults (aged 18 and over), and the role of thrombophilia testing. It aims to clarify which diagnostic tests should be used, reduce variation in pharmacological therapies, and provide guidance on when thrombophilia testing is useful.
For further information visit: https://www.nice.org.uk/guidance/cg144
1. NICE guideline 89. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. March 2018. Available at: https://www.nice.org.uk/guidance/ng89
2. NICE clinical guideline 144. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. June 2012. Available at: https://www.nice.org.uk/guidance/cg144
The Scottish Intercollegiate Guidelines Network (SIGN)
Prevention and management of venous thromboembolism1
The guideline identifies adult patient groups at risk of venous thromboembolism and describes the available methods of prophylaxis, with general recommendations about efficacy, safety, and how they should be used. Appropriate methods of prophylaxis for specific patient groups are considered. Diagnosis of deep vein thrombosis and pulmonary embolism are described, including the use of diagnostic algorithms incorporating D-dimer assay. Recommendations are made on treatment options for thrombosis in various anatomical regions.
For further information visit: http://www.sign.ac.uk/sign-122-prevention-and-management-of-venous-thromboembolism.html
Acute coronary syndrome2
This guideline provides recommendations for the management of patients with ACS within the first 12 hours and up to hospital discharge. With the exception of dual antiplatelet therapy with aspirin and P2Y12-receptor antagonists, this guideline does not make recommendations for: long-term treatment following discharge from hospital. It does not cover prehospital management or the management of undifferentiated chest pain or acute heart failure.
For further information visit: http://www.sign.ac.uk/sign-148-acute-coronary-syndrome.html
1. SIGN Guideline 122, 2010. Updated October 2014. Available at: www.sign.ac.uk/assets/sign122.pdf
2. Scottish Intercollegiate Guidelines Network (SIGN). Acute Coronary Syndromes: A national clinical guideline. Edinburgh: SIGN; April 2016. (SIGN publication no. 148). Available at: www.sign.ac.uk/assets/sign148.pdf
American College of Clinical Pharmacy (ACCP)
AT10 (ACCP, 2016)
Antithrombotic Therapy for VTE Disease1
For further information visit: https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
Additional Pulmonary Vascular Guidelines and Expert reports are available here: http://www.chestnet.org/Guidelines-and-Resources/CHEST-Guideline-Topic-Areas/Pulmonary-Vascular
1. Kearon C et al. Chest 2016;149:315–352.
American Society of Clinical Oncology (ASCO)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: Update1
These guidelines provide recommendations about the prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer.
For further information visit: https://www.asco.org/research-guidelines/quality-guidelines/guidelines/supportive-care-and-treatment-related-issues
1. Lyman GH et al. J Clin Oncol 2015;33:654–656.
*Including, but not limited to: congestive cardiac failure (NYHA class III or IV), acute respiratory failure or acute infection, who also have a predisposing risk factor for VTE such as age over 75 years, obesity, cancer or previous history of VTE.~
†In patients with chronic renal insufficiency or acute renal failure.
PP-FRA-GBR-0206. March 2020